Table 2.
Cumulative incidence of serious late cardiopulmonary conditions among Hodgkin lymphoma survivors (n = 2996) from the Childhood Cancer Survivor Study by select treatment groups
| Treatment group | Cumulative incidence by age 30 years, % (95% CI) |
|---|---|
| Contemporary therapy (n = 229)* | 8.2 (3.7-15.0) |
| Chemotherapy† without chest radiation (n = 216) | 2.8 (0.9-6.6) |
| Salvage therapy (n = 296)‡ | 12.4 (8.4-17.2) |
| Chest radiotherapy ≥35 Gy (n = 1215)§ | 7.1 (5.6-8.9) |
From Oeffinger et al.8
*
Based on Children's Oncology Group protocols AHOD0431 (low risk) and HOD0031 (intermediate risk) with doxorubicin <205 mg/m2, cyclophosphamide 2000 to 3900 mg/m2, any vincristine, and prednisone, with or without involved field radiation ≤26 Gy.
†
Any anthracycline plus any alkylator.
‡
Treatment for relapse with or without autologous or allogeneic hematopoietic cell transplantation within 5 years of cancer diagnosis.
§
With or without chemotherapy; not mutually exclusive with salvage therapy group.